Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.
Beijing SL Pharmaceutical Dividend Announcement
• Beijing SL Pharmaceutical announced a annually dividend of ¥0.15 per ordinary share which will be made payable on 2024-07-04. Ex dividend date: 2024-07-04
• Beijing SL Pharmaceutical annual dividend for 2024 was ¥0.15
• Beijing SL Pharmaceutical annual dividend for 2023 was ¥0.10
• Beijing SL Pharmaceutical's trailing twelve-month (TTM) dividend yield is 1.96%
• Beijing SL Pharmaceutical's dividend growth over the last five years (2018-2023) was -27.52% year
• Beijing SL Pharmaceutical's dividend growth over the last ten years (2013-2023) was -8.76% year
Beijing SL Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-07-04 | ¥0.15 | annually | 2024-07-04 |
2023-06-28 | ¥0.10 | annually | 2023-06-28 |
2022-06-29 | ¥0.10 | annually | 2022-06-29 |
2021-07-07 | ¥0.10 | annually | 2021-07-07 |
2020-07-08 | ¥0.20 | annually | 2020-07-08 |
2019-07-04 | ¥0.30 | annually | 2019-07-04 |
2018-05-04 | ¥0.50 | annually | 2018-05-04 |
2017-07-05 | ¥0.20 | annually | 2017-07-05 |
2016-07-22 | ¥0.20 | annually | |
2015-07-15 | ¥0.30 | annually | |
2014-07-04 | ¥0.20 | annually | |
2013-05-28 | ¥0.25 | annually |
Beijing SL Pharmaceutical Dividend per year
Beijing SL Pharmaceutical Dividend growth
Beijing SL Pharmaceutical Dividend Yield
Beijing SL Pharmaceutical current trailing twelve-month (TTM) dividend yield is 1.96%. Interested in purchasing Beijing SL Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Beijing SL Pharmaceutical Financial Ratios
Beijing SL Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Beijing SL Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Beijing SL Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Beijing SL Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Beijing SL Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Beijing SL Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Beijing SL Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Beijing SL Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Beijing SL Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Beijing SL Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Beijing SL Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Beijing SL Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.